LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

Search

Guardant Health Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

90.2 -0.7

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

89

Max

92.15

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-36M

-128M

Pardavimai

16M

281M

Pelnas, tenkantis vienai akcijai

-0.5

Pelno marža

-45.684

Darbuotojai

2,490

EBITDA

-37M

-119M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+45.37% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-04-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-1.7B

12B

Ankstesnė atidarymo kaina

90.9

Ankstesnė uždarymo kaina

90.2

Naujienos nuotaikos

By Acuity

50%

50%

146 / 351 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Guardant Health Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-10 20:38; UTC

Uždarbis

Oracle Raises 2027 Sales Outlook Amid AI Demand, Restructuring

2026-03-10 23:57; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-03-10 23:57; UTC

Rinkos pokalbiai

Risks Rising on Australian Bank Valuation Multiples -- Market Talk

2026-03-10 23:47; UTC

Rinkos pokalbiai

Nikkei May Rise as Concerns About Energy Costs Ease -- Market Talk

2026-03-10 23:37; UTC

Įsigijimai, susijungimai, perėmimai

Yangzijiang Shipbuilding to Acquire Poseidon Stake for US$825.7M

2026-03-10 23:37; UTC

Įsigijimai, susijungimai, perėmimai

Yangzijiang Shipbuilding to Buy 10% Stake in Poseidon

2026-03-10 23:37; UTC

Įsigijimai, susijungimai, perėmimai

Yangzijiang Shipbuilding to Fund Deal With Internal Cash Resources

2026-03-10 23:37; UTC

Įsigijimai, susijungimai, perėmimai

Yangzijiang Shipbuilding to Buy Stake From Fairfax, Washington Family Affiliates

2026-03-10 23:35; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Gold Edges Higher as It Faces Opposing Forces -- Market Talk

2026-03-10 23:06; UTC

Uždarbis

Oracle Raises 2027 Sales View as AI Demand Outpaces Supply -- Update

2026-03-10 22:51; UTC

Svarbiausios naujienos

Deleted Tweet From Energy Secretary Sends Oil Markets on Another Wild Ride -- Updated

2026-03-10 21:39; UTC

Įsigijimai, susijungimai, perėmimai

Bill Ackman Has a Stroke of Genius. Buy His New Fund and Get Shares of His Pershing Square IPO. -- Barrons.com

2026-03-10 21:21; UTC

Uždarbis

Oracle Stock Jumps on Earnings Beat. Its Cloud Business Is Taking Over. -- Barrons.com

2026-03-10 21:15; UTC

Uždarbis

Franco-Nevada: 2026 Total GEOs Expected to Range From 510,000 to 570,000 Ounces

2026-03-10 21:15; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Skydance's Stock Fades. The Warner Bros. Merger Will Take Years to Pay Off, BofA Says. -- Barrons.com

2026-03-10 21:14; UTC

Uždarbis

Franco-Nevada: Methodology Replaces Previous Variable GEO Conversion Ratios Based on Prevailing Market Prices

2026-03-10 21:13; UTC

Uždarbis

Franco-Nevada: Beginning in 2026, Company Will Be Adopt Fixed GEO Conversion Ratios Based on the Pricing Assumptions Outlined in 2026 Guidance

2026-03-10 21:12; UTC

Uždarbis

Franco-Nevada 4Q Rev $597.3M >FNV

2026-03-10 21:12; UTC

Uždarbis

Franco-Nevada 4Q EPS $1.90

2026-03-10 20:57; UTC

Uždarbis

Oracle Stock Jumps on Earnings Beat -- Barrons.com

2026-03-10 20:50; UTC

Rinkos pokalbiai
Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2026-03-10 20:44; UTC

Uždarbis

Oracle Stock Jumps on Earnings Beat -- Barrons.com

2026-03-10 20:34; UTC

Rinkos pokalbiai
Uždarbis

Global Equities Roundup: Market Talk

2026-03-10 20:34; UTC

Rinkos pokalbiai
Uždarbis

Oracle Building More Software for Less Money After Restructuring -- Market Talk

2026-03-10 20:23; UTC

Uždarbis

Oracle Stock Jumps on Earnings Beat -- Barrons.com

2026-03-10 20:16; UTC

Uždarbis

NIO Stock Jumps After Earnings. How the EV Maker Delivered a Surprise Profit. -- Barrons.com

2026-03-10 20:14; UTC

Uždarbis

Oracle Has Not Yet Initiated At-The-Market Equity Portion of Financing Program >ORCL

2026-03-10 20:14; UTC

Uždarbis

Oracle Said In February It Intends to Raise Up to $50 B Dollars in Debt and Equity Financing >ORCL

2026-03-10 20:13; UTC

Uždarbis

Oracle Raised $30 B Through Combination of Investment Grade Bonds and Mandatory Convertible Preferred Stk Within Days of Feb Announcement >ORCL

2026-03-10 20:12; UTC

Uždarbis

Oracle Stock Jumps on Earnings Beat -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Guardant Health Inc Prognozė

Kainos tikslas

By TipRanks

45.37% į viršų

12 mėnesių prognozė

Vidutinis 132.58 USD  45.37%

Aukščiausias 175 USD

Žemiausias 110 USD

Remiantis 21 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Guardant Health Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

21 ratings

20

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

38.86 / 47.41Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

146 / 351 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat